Genetron Holdings (NASDAQ:GTH) shares are trading lower after the company reported worse-than-expected Q1 ADS and sales results.
Genetron is currently down 5.24% to a price of $21.25. The stock s volume is currently 297.19 thousand, which is roughly 99.53% of its recent 30-day volume average of 298.60 thousand.
The stock s 50-day moving average was $20.79 at the time this article was published. Over the past fifty-two weeks, the price has risen as high as $31.54 and fallen to a low of $9.03.
Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.
I-Mab
I-Mab is a clinical-stage biopharmaceutical company that commits to the discovery, development, and commercialization of novel or highly differentiated biologics. The company aims to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. As a company not involved in COVID-19 vaccines, the health care company stock has been performing extremely well. Impressively, it has risen by more than 220% over the past year with its bullish trend still intact.
Investors have been keeping their eyes on IMAB stock in response to the company’s early data on Uliledlimab/Atezolizumab combo in advanced cancer settings. More detailed data of the trial will be unveiled at the 2021 American Society of Clinical Oncology Annual Meeting which will be taking place next month.
Genetron Health Announces Strategic Partnership with Siemens Healthineers to Promote Precision Oncology for Lung Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Published: May 10, 2021
Closes $5 million Series A financing
Appoints Pritesh J. Gandhi, PharmD, as Chief Executive Officer and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations
Announces exclusive license of TellDx platform to Genetron Holdings Limited for China
Secures Deployment of TellDx at ARUP Laboratories, Inc
BEVERLY, Mass., May 10, 2021 (GLOBE NEWSWIRE)
TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection and treatment of cancer through its unique and proprietary circulating tumor cell (CTC) technology, TellDx, and complementary therapeutics platform, TellRx, today announced the closing of a $5 million Series A financing. Concurrent with the close, the Company announced the appointments of Pritesh J. Gandhi, PharmD, as Chief Executive Officer (CEO) and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations; an exclusive license of the TellDx platform to Genetron Holdi
Genetron Health to Present at Upcoming Investor Conferences globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.